KRAS and neoplasm: Moreover, CRISPR/Cas9-mediated Kras knockout in tumor cells derived from the KPC mouse model showed pathway enrichment for EMT and TGFβ signaling, hinting that ablation of Kras drives a subtype switch towards the squamous subtype (Ischenko et al., 2021).